Mortality in Non-cystic Fibrosis Bronchiectasis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dr. Lieven Dupont, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT01792427
First received: February 13, 2013
Last updated: February 18, 2013
Last verified: February 2013

February 13, 2013
February 18, 2013
June 2006
October 2012   (final data collection date for primary outcome measure)
overall survival [ Time Frame: 6 years 4 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01792427 on ClinicalTrials.gov Archive Site
risk factor identification for NCFB [ Time Frame: 6 years 4 months ] [ Designated as safety issue: No ]
The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa.
risk factor identification [ Time Frame: 6 years 4 months ] [ Designated as safety issue: No ]
We wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa and evaluate the impact on survival of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension.
  • Identify cause of death [ Time Frame: 6 years 4 months ] [ Designated as safety issue: No ]
    If death occurred, the patient file was reassessed to identify cause of death.
  • risk factor identification for the survival of NCFB [ Time Frame: 6 years 4 months ] [ Designated as safety issue: No ]
    The investigators will evaluate the impact of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension on survival .
Identify cause of death [ Time Frame: 6 years 4 months ] [ Designated as safety issue: No ]
If death occurred, the patient file was reassessed to identify cause of death.
 
Mortality in Non-cystic Fibrosis Bronchiectasis
Mortality in Non-cystic Fibrosis Bronchiectasis: a Long-term Cohort Analysis

In this study we analyzed the overall survival for all newly diagnosed patients with non-cystic fibrosis bronchiectasis from June 2006 onwards. The investigators wanted to confirm the known risk factors such as age, gender, smoking history and Pseudomonas aeruginosa and evaluate the impact on survival of etiology, number of different bacteriological species in retrospective and prospective sputa, azithromycin use and presence/development of pulmonary hypertension.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

non-cystic fibrosis bronchiectasis

Non-cystic Fibrosis Bronchiectasis
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
253
December 2012
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with clinically significant and radiologically proven bronchiectasis
  • Chest CT scan confirming the presence of bronchiectatic lesions and had symptoms of chronic productive cough
  • Bronchiectasis was deemed to be present if there was one or more of the following criteria: a bronchoarterial ratio greater than 1, lack of tapering of the bronchi and visualization of bronchi within 1 cm of costal or paravertebral pleura or abutting the mediastinal pleura

Exclusion Criteria:

  • diagnosis of cystic fibrosis
  • underlying tumoral problem causing the bronchiectatic lesions (postradiotherapy, secondary immunodeficiency due to chemotherapy or postinfectious due to tumoral obstruction)
  • patients with asymptomatic traction bronchiectasis caused by interstitial lung disease
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT01792427
B51060, B32220084152
No
Dr. Lieven Dupont, Universitaire Ziekenhuizen Leuven
Universitaire Ziekenhuizen Leuven
Not Provided
Study Director: Pieter Goeminne, MD Universitaire Ziekenhuizen Leuven
Universitaire Ziekenhuizen Leuven
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP